Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

A Parallel Approach to 7-(Hetero)arylpyrazolo[1,5- a]pyrimidin-5-ones.

Schmitt DC, Niljianskul N, Sach NW, Trujillo JI.

ACS Comb Sci. 2018 May 14;20(5):256-260. doi: 10.1021/acscombsci.8b00032. Epub 2018 Apr 6.

PMID:
29618198
2.

A platform for automated nanomole-scale reaction screening and micromole-scale synthesis in flow.

Perera D, Tucker JW, Brahmbhatt S, Helal CJ, Chong A, Farrell W, Richardson P, Sach NW.

Science. 2018 Jan 26;359(6374):429-434. doi: 10.1126/science.aap9112.

PMID:
29371464
3.

Visible-Light-Initiated Manganese Catalysis for C-H Alkylation of Heteroarenes: Applications and Mechanistic Studies.

Nuhant P, Oderinde MS, Genovino J, Juneau A, Gagné Y, Allais C, Chinigo GM, Choi C, Sach NW, Bernier L, Fobian YM, Bundesmann MW, Khunte B, Frenette M, Fadeyi OO.

Angew Chem Int Ed Engl. 2017 Nov 27;56(48):15309-15313. doi: 10.1002/anie.201707958. Epub 2017 Oct 26.

PMID:
28960645
4.

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Planken S, Behenna DC, Nair SK, Johnson TO, Nagata A, Almaden C, Bailey S, Ballard TE, Bernier L, Cheng H, Cho-Schultz S, Dalvie D, Deal JG, Dinh DM, Edwards MP, Ferre RA, Gajiwala KS, Hemkens M, Kania RS, Kath JC, Matthews J, Murray BW, Niessen S, Orr ST, Pairish M, Sach NW, Shen H, Shi M, Solowiej J, Tran K, Tseng E, Vicini P, Wang Y, Weinrich SL, Zhou R, Zientek M, Liu L, Luo Y, Xin S, Zhang C, Lafontaine J.

J Med Chem. 2017 Apr 13;60(7):3002-3019. doi: 10.1021/acs.jmedchem.6b01894. Epub 2017 Mar 29.

PMID:
28287730
5.

Strain-Release Heteroatom Functionalization: Development, Scope, and Stereospecificity.

Lopchuk JM, Fjelbye K, Kawamata Y, Malins LR, Pan CM, Gianatassio R, Wang J, Prieto L, Bradow J, Brandt TA, Collins MR, Elleraas J, Ewanicki J, Farrell W, Fadeyi OO, Gallego GM, Mousseau JJ, Oliver R, Sach NW, Smith JK, Spangler JE, Zhu H, Zhu J, Baran PS.

J Am Chem Soc. 2017 Mar 1;139(8):3209-3226. doi: 10.1021/jacs.6b13229. Epub 2017 Feb 20.

6.

Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners.

Elleraas J, Ewanicki J, Johnson TW, Sach NW, Collins MR, Richardson PF.

Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3590-5. doi: 10.1002/anie.201509240. Epub 2016 Feb 16.

PMID:
26880581
7.

Organic chemistry. Strain-release amination.

Gianatassio R, Lopchuk JM, Wang J, Pan CM, Malins LR, Prieto L, Brandt TA, Collins MR, Gallego GM, Sach NW, Spangler JE, Zhu H, Zhu J, Baran PS.

Science. 2016 Jan 15;351(6270):241-6. doi: 10.1126/science.aad6252.

8.

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.

Johnson TW, Richardson PF, Bailey S, Brooun A, Burke BJ, Collins MR, Cui JJ, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Huang Q, Kania RS, Kath JC, Lam H, Lam JL, Le PT, Lingardo L, Liu W, McTigue M, Palmer CL, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski S, Zhu H, Zhu J, Zou HY, Edwards MP.

J Med Chem. 2014 Jun 12;57(11):4720-44. doi: 10.1021/jm500261q. Epub 2014 Jun 3.

PMID:
24819116
9.

Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook AS, Cui JJ, Dack KN, Deal JG, Deng YL, Dinh D, Engstrom LD, He M, Hoffman J, Hoffman RL, Johnson PS, Kania RS, Lam H, Lam JL, Le PT, Li Q, Lingardo L, Liu W, Lu MW, McTigue M, Palmer CL, Richardson PF, Sach NW, Shen H, Smeal T, Smith GL, Stewart AE, Timofeevski S, Tsaparikos K, Wang H, Zhu H, Zhu J, Zou HY, Edwards MP.

J Med Chem. 2014 Feb 27;57(4):1170-87. doi: 10.1021/jm401805h. Epub 2014 Feb 6.

10.

Synthesis of aryl ethers via a sulfonyl transfer reaction.

Sach NW, Richter DT, Cripps S, Tran-Dubé M, Zhu H, Huang B, Cui J, Sutton SC.

Org Lett. 2012 Aug 3;14(15):3886-9. doi: 10.1021/ol301615z. Epub 2012 Jul 17.

PMID:
22799458
11.

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

Liu KK, Zhu J, Smith GL, Yin MJ, Bailey S, Chen JH, Hu Q, Huang Q, Li C, Li QJ, Marx MA, Paderes G, Richardson PF, Sach NW, Walls M, Wells PA, Baxi S, Zou A.

ACS Med Chem Lett. 2011 Sep 19;2(11):809-13. doi: 10.1021/ml200126j. eCollection 2011 Nov 10. Erratum in: ACS Med Chem Lett. 2012 Feb 9;3(2):170. Baxi, Sangita [added].

12.

Scalable synthesis of 1-bicyclo[1.1.1]pentylamine via a hydrohydrazination reaction.

Bunker KD, Sach NW, Huang Q, Richardson PF.

Org Lett. 2011 Sep 2;13(17):4746-8. doi: 10.1021/ol201883z. Epub 2011 Aug 11.

PMID:
21834522
13.

3-Amino-5-bromo-2-iodo-pyridine.

Bunker KD, Sach NW, Nukui S, Rheingold AL, Yanovsky A.

Acta Crystallogr Sect E Struct Rep Online. 2008 Dec 6;65(Pt 1):o28. doi: 10.1107/S1600536808040452.

Supplemental Content

Support Center